British Journal of Cancer - Table of Contents alert Volume 119 Issue 10

TABLE OF CONTENTS Volume 119, Issue 10 In this issue Review Article Article Also new AOP Review Article Harnessing the immune system in glioblastoma Nicholas F. Brown, Thomas J. Carter, Diego Ottaviani & Paul Mulholland British Journal of Cancer 2018 119 :1171 - 1181; November 05, 2018; 10.1038/s41416-018-0258-8 Abstract | Full Text Article A randomised controlled trial of an advance care planning intervention for patients with incurable cancer Stephanie B. Johnson, Phyllis N. Butow, Melanie L. Bell, Karen Detering, Josephine M. Clayton et al. British Journal of Cancer 2018 119 :1182 - 1190; October 29, 2018; 10.1038/s41416-018-0303-7 Abstract | Full Text Irradiance controls photodynamic efficacy and tissue heating in experimental tumours: implication for interstitial PDT of locally advanced cancer Gal Shafirstein, David A. Bellnier, Emily Oakley, Sasheen Hamilton, Michael Habitzruther et al. British Journal of Cancer 2018 119 :1191 - 1199; October 24, 2018; 10.1038/s41416-018-0210-y Abstract | Full Text A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours Amit Maity, Rosemarie Mick, Alexander C. Huang, Sangeeth M. George, Michael D. Farwell et al. British Journal of Cancer 2018 119 :1200 - 1207; October 15, 2018; 10.1038/s41416-018-0281-9 Abstract | Full Text Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, Denis Pezet, Gael Deplanque et al. British Journal of Cancer 2018 119 :1208 - 1214; October 15, 2018; 10.1038/s41416-018-0246-z Abstract | Full Text Manual lymphatic drainage adds no further volume reduction to Complete Decongestive Therapy on breast cancer-related lymphoedema: a multicentre, randomised, single-blind trial Mette Tambour, Marianne Holt, Anette Speyer, Robin Christensen & Bibi Gram British Journal of Cancer 2018 119 :1215 - 1222; October 24, 2018; 10.1038/s41416-018-0306-4 Abstract | Full Text Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer Viswanath Gunda, Benjamin Gigliotti, Dorothy Ndishabandi, Tameem Ashry, Michael McCarthy et al. British Journal of Cancer 2018 119 :1223 - 1232; October 17, 2018; 10.1038/s41416-018-0296-2 Abstract | Full Text pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry Gemma N. Jones, Claire Rooney, Nicola Griffin, Martine Roudier, Lucy A. Young et al. British Journal of Cancer 2018 119 :1233 - 1243; November 02, 2018; 10.1038/s41416-018-0286-4 Abstract | Full Text Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data Anne Trinh, Claudia Lädrach, Heather E. Dawson, Sanne ten Hoorn, Peter J. K. Kuppen et al. British Journal of Cancer 2018 119 :1244 - 1251; November 02, 2018; 10.1038/s41416-018-0230-7 Abstract | Full Text The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response Marzia Del Re, Paola Bordi, Eleonora Rofi, Giuliana Restante, Simona Valleggi et al. British Journal of Cancer 2018 119 :1252 - 1258; November 06, 2018; 10.1038/s41416-018-0238-z Abstract | Full Text Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis Kinga Walaszek, Elyse E. Lower, Piotr Ziolkowski & Georg F. Weber British Journal of Cancer 2018 119 :1259 - 1266; October 24, 2018; 10.1038/s41416-018-0228-1 Abstract | Full Text Epigenetically regulated miR-1247 functions as a novel tumour suppressor via MYCBP2 in methylator colon cancers Jennifer Liang, Wenchao Zhou, Nneha Sakre, Jennifer DeVecchio, Sylvain Ferrandon et al. British Journal of Cancer 2018 119 :1267 - 1277; October 15, 2018; 10.1038/s41416-018-0249-9 Abstract | Full Text The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death Maciej Kaliszczak, Erich van Hechanova, Yunqing Li, Hibah Alsadah, Katarzyna Parzych et al. British Journal of Cancer 2018 119 :1278 - 1287; October 15, 2018; 10.1038/s41416-018-0232-5 Abstract | Full Text Overinterpretation and misreporting of prognostic factor studies in oncology: a systematic review Emmanuelle Kempf, Jennifer A. de Beyer, Jonathan Cook, Jane Holmes, Seid Mohammed et al. British Journal of Cancer 2018 119 :1288 - 1296; October 24, 2018; 10.1038/s41416-018-0305-5 Abstract | Full Text Statin use and risk of contralateral breast cancer: a nationwide cohort study Rikke Langballe, Deirdre Cronin-Fenton, Christian Dehlendorff, Maj-Britt Jensen, Bent Ejlertsen et al. British Journal of Cancer 2018 119 :1297 - 1305; October 24, 2018; 10.1038/s41416-018-0252-1 Abstract | Full Text Advertisement Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours. Click here to sign up. Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. This email has been sent to edgeblog.alerts.2011.001@gmail.com. If you no longer wish to receive the email alerts from British Journal of Cancer click here to unsubscribe . If you wish to discontinue all email services from Nature Research please click here to unsubscribe . For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Macmillan Publishers Limited is a company incorporated in England & Wales under company number 785998 & whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. Nature Research | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved.